undamentalytics Newsletter
Sign in

Adial Pharmaceuticals, Inc. (ADIL) stock

Add to watchlist

Add holding +

NASDAQ: ADIL Nasdaq Biotechnology Next results ~November 13, 2026

Adial Pharmaceuticals, Inc. is a US-listed company in the biotechnology industry. Its financial year ends in December.

Who’s trading

What company insiders, investment funds and members of Congress have been doing with the stock, from their own filings.

  • Insiders1 buying, 0 selling5 purchases and 0 sales by directors and officers, last 12 monthsInsider trades
  • Funds7 adding, 4 cuttingOf 1 active managers that changed their stake, 1 added; quarter to June 30, 2026Fund buyers and sellers

The Fundamentalytics view

Next results ~November 13, 2026 (estimated)

Current signal Free cash flow diverging from earnings: TTM free cash flow fell 71.7% while net income fell 584.1%: a 512pp divergence.

Assembled from SEC-filed figures — the full workings are on this page and in our methodology. Observations, not recommendations.

Highlights

How we pick these

Strengths

Nothing in Adial Pharmaceuticals, Inc.'s latest figures clears our strength thresholds.

Things to watch

  • Results due soon. Results are expected around 13 November; the share price can move sharply on the day.
  • Share dilution. Diluted shares rose 39.0% in a year.
  • Missing expectations. Earnings per share fell short of the consensus estimate in 2 of the last four quarters.

Latest results

Earnings per share
-$1.29 against an average estimate of -$0.91: missed by 41.8%

Adial Pharmaceuticals' figures from its SEC filings and results release; estimates are the analysts' average. Not a recommendation.

Price chart

  • 1 day+5.0%

Closing prices to 2026-11-02. Price change only, dividends excluded.

Loading chart…

Third-party market data · may be delayed

At a glance

Trailing twelve months, from SEC filings

Earnings

Last results
August 17, 2026
Next results (est.)
November 13, 2026

News & updates

Updated October 31, 2026

Company announcements, filed results and changes that matter to shareholders.

  1. Leadership
  2. Announcement
  3. Announcement
  4. Leadership
  5. Agreement
  6. Share issue
  7. Results
  8. Leadership

Refreshed hourly when new source data is available. Summaries are checked against company releases and SEC filings. Company announcement headlines are labelled when a checked summary is unavailable.

Valuation

Adial Pharmaceuticals, Inc. valuation models and calculator

No model value for Adial Pharmaceuticals, Inc. at the moment. Current status: limited reported history: available models are shown without a Buy/Hold/Sell rating. Available reported financials are shown below.

Fundamentalytics rating

model v1.6 · 2026-11-03

Not rated: limited reported history: available models are shown without a Buy/Hold/Sell rating.

Valuation models

We value Adial Pharmaceuticals, Inc. as an operating company, with every model that fits that kind of business. Cost of equity 9.9%: the 10-year Treasury yield (4.9%) plus a beta of 1.1 times a 4.5% equity risk premium.

Value per share by model
Model Value per share In the combined value?
Price-to-earnings vs peers Earnings per share times peers' typical (harmonic-mean) price-to-earnings. — Does not apply: no positive earnings in the latest twelve months
Residual income Book value plus the present value of returns above the cost of equity, fading over ten years. — Does not apply: book value or earnings not available
Justified price-to-book Book value times (return on equity - growth) / (cost of equity - growth): steady-state returns. — Does not apply: return on equity is not positive
Revenue-to-maturity model Revenue grown to maturity with the cash margin moving to the industry's; for companies not yet profitable. — Does not apply: revenue and margins don't support a positive value
Price-to-sales vs peers Sales per share times peers' typical price-to-sales; used only when earnings are negative. — Does not apply: no positive revenue in the latest twelve months
Combined value Weighted average of the models that apply: the primary model (price-to-earnings vs peers) counts double. Models more than 5x or less than 0.2x the share price, or more than 3x away from the other models' median, are left out. — No model applies: the filings don’t yet support a value.

Different models fail in different ways, so where several apply we average them rather than trust one. Peer-based models compare Adial Pharmaceuticals, Inc. with Biotechnology in our coverage, using third-party market data. Model values are estimates under stated assumptions, updated as new filings arrive; not price targets or investment advice. How each model works.

Moat

Not assessed: fewer than five years of comparable figures in the filings. AI disruption exposure for this industry: Medium.

A rules-based reading of reported figures, not a forecast and not investment advice. How the score is built: methodology.

Forecasts and guidance

Analysts' consensus

Fiscal yearEPSGrowthRevenueGrowth
Current −$1.05 +91% — 0%
Next −$7.45 −610% — 0%

How the EPS forecast has moved

The consensus EPS forecast for the current fiscal year is −82.8% on 90 days ago. In the last 30 days, 1 analyst raised Adial Pharmaceuticals, Inc.'s forecast and 0 cut it.

Consensus EPS forecast Adial Pharmaceuticals, Inc., last 90 days
−$15.00 −$10.00 −$5.00 $0.00 90 days ago 60 days ago Now Current fiscal year, 90 days ago: −$6.12 Current fiscal year, 60 days ago: −$5.26 Current fiscal year, Now: −$1.05 −$1.05 Next fiscal year, 90 days ago: −$2.59 Next fiscal year, 60 days ago: −$2.49 Next fiscal year, 30 days ago: −$14.25 Next fiscal year, 7 days ago: −$14.25 Next fiscal year, Now: −$7.45 −$7.45

Average of analysts' published estimates (third-party data).

View chart data
Period Current fiscal yearNext fiscal year
90 days ago −$6.12−$2.59
60 days ago −$5.26−$2.49
Now −$1.05−$14.25

Earnings against estimates

Quarter toEstimateActualSurprise
Jun 2026 −$0.91 −$1.29 −41.8%
Mar 2026 −$2.25 −$1.48 +34.2%
Dec 2025 −$2.13 −$11.48 −439.0%
Sept 2025 −$3.50 −$2.00 +42.9%

Adjusted EPS as companies report it, against the average analyst estimate.

Analyst recommendations

4 analysts, Oct 2026
Buy375%
Hold125%
Sell00%

Monthly trend

  1. Oct 20261214

Counts of recommendations published by analysts covering Adial Pharmaceuticals, Inc., by month. Source: Aggregated broker recommendations (third-party data). Aggregated counts only: we do not reproduce any firm's recommendation or price target, and these are not Fundamentalytics ratings.

Positioning

Short interest
6.9%
of tradable shares
Days to cover
4.34
at average volume
Short interest, 1 month
−14%
to October 15, 2026
Held by institutions
30%
of shares
Held by insiders
7.1%
of shares
Employees
5
full time

Consensus figures average analysts' published estimates (third-party data); guidance is the company's own. Neither is our forecast. Short interest is reported twice a month and lags. Market data may be delayed.

This section is general information, not investment advice or a personal recommendation, and it does not take account of your objectives or circumstances. Forecasts and guidance are estimates, not promises: companies miss their own guidance and analysts' figures are often revised. Prices can fall as well as rise, and you can lose money. See our disclaimer.

Share-price performance

Market data may be delayed

Price behaviour

52-week range
Not enough history
From 52-week high
—
vs 50-day average
—
vs 200-day average
—
Volatility (1 year)
—
Beta vs S&P 500
—

Volatility is the annualised standard deviation of daily returns. Beta 1.5 means the shares typically moved 1.5% for each 1% move in the S&P 500 over the past year. Prices to November 2, 2026.

Fundamentals

Data: SEC EDGAR XBRL company facts (as filed in 10-K/10-Q); forms 10-K, 10-Q, 10-Q/A. Generated November 3, 2026. Definitions in our methodology.

Who owns it

Funds buying and selling
Reported value
$334,555
Institutions reporting
17
Shares held vs prior quarter
▲ 283.0%
Positions opened / closed
4 / 2

Top buyers and sellers, Q2 2026: 7 institutions bought and 4 sold ; the biggest buyer was Jane Street Group, LLC (+32K shares) and the biggest seller Geode Capital Management, LLC (−12K). See which funds bought and sold →

Largest reported holders, June 30, 2026
Manager Value Shares Share of 13F value Shares QoQ
Jane Street Group, LLC $82,225 32K 24.6% New
Citadel Advisors LLC $75,640 30K 22.6% New
UBS Group AG $49,017 19K 14.7% ▲ 3432.7%
Stonex Group Inc. $35,671 20K 10.7% New
Geode Capital Management, LLC $31,725 12K 9.5% ▼ 48.9%
China Universal Asset Management Co., Ltd. $20,480 8K 6.1% New
Vanguard Fiduciary Trust Co $15,050 6K 4.5% 0.0%
Vanguard Capital Management LLC $14,927 6K 4.5% ▲ 1515.2%
Manchester Capital Management LLC $4,923 2K 1.5% 0.0%
Tower Research Capital LLC (TRC) $3,633 1K 1.1% ▲ 4.6%
Blackrock, Inc. $778 0K 0.2% ▼ 72.6%
Raffa Wealth Management, LLC $212 0K 0.1% 0.0%

From Form 13F filings with the SEC ( quarterly data sets), as reported by each manager for June 30, 2026 and filed up to 45 days later. 13F reports cover long US-listed positions of managers above $100M only, so this is not Adial Pharmaceuticals, Inc.'s complete shareholder register. Values are as reported by the filers .

Insider trading activity

Full insider history and chart
Insider purchases History → $106,329 5 trades by 1 insider, last 12 months Insider sales History → $0 0 trades by 0 insiders
Net ▲ $106,329 net buying
Insider Date Trade Shares Price Value
Coastlands Capital Lp 10% owner July 16, 2026 Buy 1,233 $2.75 $3,391
Coastlands Capital Lp 10% owner July 14, 2026 Buy 2,000 $2.65 $5,300
Coastlands Capital Lp 10% owner July 10, 2026 Buy 1,700 $2.70 $4,590
Coastlands Capital Lp 10% owner July 9, 2026 Buy 10,053 $2.79 $28,048
Coastlands Capital Lp 10% owner June 29, 2026 Buy 25,000 $2.60 $65,000

From insiders' Form 4 filings with the SEC. Excludes awards, option exercises and shares withheld for tax. "Pre-set plan" means the filing marks the trade as made under a Rule 10b5-1 plan. See every insider trade since five years ago, on a price chart.

Earnings dates and SEC filings

Results announcements

Next expected around November 13, 2026 estimated from the company's past filing pattern, not announced

  • August 17, 2026
  • May 11, 2026
  • March 6, 2026
  • November 14, 2025
  • August 14, 2025
  • May 15, 2025

Recent SEC filings

Data status

When each part of this page on Adial Pharmaceuticals, Inc. was last updated.

DataLast updatedSource
Share priceExchange closing prices
News and updatesCompany releases and SEC 8-K filings
Analyst estimatesAggregated analyst estimates
Valuation and scoresOur models, from the filed figures

How we build and check these figures: methodology and data sources.

Adial Pharmaceuticals, Inc. in brief

What does Adial Pharmaceuticals, Inc. do?
Adial Pharmaceuticals, Inc. is a US-listed company in the biotechnology industry. Its financial year ends in December.
What is Adial Pharmaceuticals, Inc.'s stock ticker?
Adial Pharmaceuticals, Inc. trades under the ticker ADIL on Nasdaq. This page brings together its financial statements, valuation models, ownership and recent company updates.
Who are Adial Pharmaceuticals, Inc.'s largest institutional shareholders?
By value reported in 13F filings for June 30, 2026, the largest reported holders are Jane Street Group, LLC, Citadel Advisors LLC and UBS Group AG. 13F reports cover long US-listed positions of managers above $100M, filed up to 45 days after quarter end.
Are insiders buying or selling Adial Pharmaceuticals, Inc. stock?
Over the last 12 months, Adial Pharmaceuticals, Inc.'s directors and officers reported 5 open-market purchases and 0 sales on Form 4. The insider trading page charts every trade.
When is Adial Pharmaceuticals, Inc.'s next earnings date?
Around November 13, 2026, estimated from the spacing of its past results announcements (8-K filings). That is an estimate, not a confirmed date — Adial Pharmaceuticals, Inc. announces its own schedule.